18:23 , Nov 30, 2018 |  BC Week In Review  |  Company News

NICE recommends Keytruda combo in first-line NSCLC

U.K.’s NICE recommended in draft guidance anti-PD-1 mAb Keytruda pembrolizumab from Merck & Co. Inc. (NYSE:MRK) for use in combination with chemotherapy through the Cancer Drug Fund for untreated, metastatic non-squamous non-small cell lung cancer....
00:01 , Nov 22, 2018 |  BC Extra  |  Company News

NICE recommends Keytruda combo in first-line NSCLC

U.K.’s NICE recommended in draft guidance anti-PD-1 mAb Keytruda pembrolizumab from Merck & Co. Inc. (NYSE:MRK) for use in combination with chemotherapy through the Cancer Drug Fund for untreated, metastatic non-squamous non-small cell lung cancer....
19:56 , Nov 2, 2018 |  BC Week In Review  |  Clinical News

FDA approves Keytruda for first-line squamous NSCLC

Merck & Co. Inc. (NYSE:MRK) said FDA approved Keytruda pembrolizumab plus carboplatin/paclitaxel or Abraxane nab-paclitaxel as first-line treatment of metastatic squamous non-small cell lung cancer (NSCLC) regardless of PD-L1 expression. The sBLA was under Priority...
17:41 , Oct 26, 2018 |  BC Week In Review  |  Financial News

Innovent raises $421M in Hong Kong IPO

Cancer and autoimmune company Innovent Biologics Inc. (HKSE:1801) priced its IPO on the Hong Kong stock exchange on Oct. 24, raising HK$3.3 billion ($421 million). Innovent sold 236.4 million shares at HK$13.98, near the top...
21:05 , Oct 24, 2018 |  BC Extra  |  Financial News

Innovent raises $421M in Hong Kong IPO

Cancer and autoimmune company Innovent Biologics Inc. (HKSE:1801) priced its IPO on the Hong Kong stock exchange, raising HK$3.3 billion ($421 million), according to a source close to the deal who asked not to be...
19:32 , Oct 19, 2018 |  BC Week In Review  |  Financial News

Reports say Innovent seeking $422M IPO in Hong Kong

Innovent Biologics Inc. (Suzhou, China) did not respond to inquiries regarding reports that the company is seeking to raise $422 million in an IPO on the Hong Kong stock exchange, which would value the company...
20:32 , Oct 5, 2018 |  BC Week In Review  |  Clinical News

Tecentriq combo leads to median OS of 18.1 months at interim analysis of Phase III for first-line NSCLC

The Genentech Inc. unit of Roche (SIX:ROG; OTCQB:RHHBY) said first-line treatment with Tecentriq atezolizumab plus chemotherapy did not show a significant improvement on the co-primary endpoint of overall survival (OS) compared with chemotherapy alone at...
21:57 , Sep 21, 2018 |  BC Extra  |  Clinical News

Innovent reports Chinese NET, NSCLC data for PD-1 mAb

Innovent Biologics Inc. (Suzhou, China) presented data this week from neuroendocrine tumor and non-small cell lung cancer cohorts in its Chinese Phase Ib trial of anti-PD-1 mAb sintilimab (IBI308). Data were presented at the Chinese...
16:38 , Sep 21, 2018 |  BC Week In Review  |  Clinical News

Innovent's PD-1 inhibitor leads to 68.4% ORR in Phase Ib for first-line NSCLC

Innovent Biologics Inc. (Suzhou, China) reported data from 19 evaluable patients with non-squamous non-small cell lung cancer (NSCLC) in cohort D of a Chinese Phase Ib trial showing that anti-PD-1 antibody sintilimab (IBI308) plus Alimta...
19:15 , Sep 14, 2018 |  BC Week In Review  |  Clinical News

Novocure planning submission for TTFields in mesothelioma

Novocure Ltd. (NASDAQ:NVCR) reported final data from the Phase II STELLAR trial to treat previously untreated unresectable malignant pleural mesothelioma showing that its Tumor Treating Fields (TTFields) plus standard of care (SOC) chemotherapy significantly improved...